Wednesday, October 14, 2026

Monetary Policy & Inflation

2 articles

30-Year Treasury Yields Break 5% as Fed Transition Widens Fiscal Risk Premium

30-Year Treasury Yields Break 5% as Fed Transition Widens Fiscal Risk Premium

30-year U.S. Treasury yields have surpassed 5% and UK gilts are at 1990s highs, as Powell's Fed departure and record sovereign debt trigger a global bond selloff. Services inflation above 3% and Iran-driven gasoline costs up $857 annually block a clean rate-cut path. Investors face mounting pressure to shorten duration and reprice credit risk across sovereign and corporate fixed income.

LM Salvado•
Energy Shock Puts Fed in Stagflation Trap as Warsh-Bessent Accord Debate Resurfaces

Energy Shock Puts Fed in Stagflation Trap as Warsh-Bessent Accord Debate Resurfaces

Iranian attacks drove European gas prices up 85% and oil above $80, triggering a 2.5% S&P 500 drop and 12% plunge in Korean stocks. The energy shock forces the Fed to choose between fighting inflation and supporting financial stability. Former Fed officials are reviving discussion of a Fed-Treasury coordination framework to manage the crisis.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com